Xiamen Amoytop Biotech Co., Ltd. (688278.SS)
CNY 78.14
(-2.42%)
CNY 78.14
(-2.42%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 680.72 Million CNY | 67.09% |
| 2022 | 406.92 Million CNY | 63.73% |
| 2021 | 248.52 Million CNY | 57.16% |
| 2020 | 158.14 Million CNY | 36.25% |
| 2019 | 116.06 Million CNY | 234.32% |
| 2018 | 34.71 Million CNY | 245.57% |
| 2017 | 10.04 Million CNY | -66.48% |
| 2016 | 29.97 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 170.51 Million CNY | 121.85% |
| 2024 Q3 | 287.7 Million CNY | 39.31% |
| 2024 Q2 | 206.52 Million CNY | 21.12% |
| 2023 Q4 | -780.48 Million CNY | -468.07% |
| 2023 FY | 679.93 Million CNY | 67.09% |
| 2023 Q3 | 212.04 Million CNY | 41.7% |
| 2023 Q1 | 118.99 Million CNY | 25.45% |
| 2023 Q2 | 149.64 Million CNY | 25.76% |
| 2022 Q1 | 89 Million CNY | 56.23% |
| 2022 FY | 406.92 Million CNY | 63.73% |
| 2022 Q4 | 94.84 Million CNY | -12.4% |
| 2022 Q3 | 108.28 Million CNY | -5.67% |
| 2022 Q2 | 114.78 Million CNY | 28.96% |
| 2021 Q3 | 83.38 Million CNY | 45.15% |
| 2021 Q4 | 56.97 Million CNY | -31.68% |
| 2021 Q2 | 57.44 Million CNY | 13.26% |
| 2021 Q1 | 50.72 Million CNY | -6.33% |
| 2021 FY | 248.52 Million CNY | 57.16% |
| 2020 Q4 | 54.15 Million CNY | 45.54% |
| 2020 Q1 | 35.62 Million CNY | -21.35% |
| 2020 Q2 | 31.15 Million CNY | -12.54% |
| 2020 Q3 | 37.2 Million CNY | 19.41% |
| 2020 FY | 158.14 Million CNY | 36.25% |
| 2019 Q1 | 9.2 Million CNY | -65.41% |
| 2019 FY | 116.06 Million CNY | 234.32% |
| 2019 Q4 | 45.29 Million CNY | 9.43% |
| 2019 Q3 | 41.39 Million CNY | 105.18% |
| 2019 Q2 | 20.17 Million CNY | 119.27% |
| 2018 Q3 | 22.23 Million CNY | 0.0% |
| 2018 Q4 | 26.6 Million CNY | 19.67% |
| 2018 FY | 34.71 Million CNY | 245.57% |
| 2017 FY | 10.04 Million CNY | -66.48% |
| 2016 FY | 29.97 Million CNY | 0.0% |